Bazán MM, Valdez GO

Language: Spanish
References: 49
Page: 1-7
PDF size: 219.61 Kb.

ABSTRACT

Advances in cancer treatment have greatly improved the survival rates of children with cancer. However, these same chemotherapeutic and / or radiological treatments can compromise long-term health. Anthracyclines, and other chemotherapeutic drugs commonly used to treat cancer, are known to be cardiotoxic, the cumulative dose, a younger diagnostic age are just some of the many risk factors that are identified with the highest risk of developing cardiotoxicity. Although cardiotoxicity can develop at any time, hence the importance of seeking cardioprotective measures to minimize the long-term damage caused by onco-hematologic-specific treatment. Given the serious long-term health consequences of these cancer treatments in childhood cancer survivors, it is essential to investigate new approaches to improve the safety of cancer treatments.

REFERENCES

1. De VitaVT Jr, Chu E. A history of cancer chemotherapy Cancer Res 2008;68(21):8643-53.

2. Chabner BA, Roberts TG Jr. Timeline Chemotherapy and the war on cancer. Nat Rev Cancer 2005;5(1):65-72.

3. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl Engl Med 2006355(15):1572-82.

4. Li J, Thompson TD, Miller JW, et al. Cancer incidence among children and adolescents in the Unite State, 2001-2003. Pediatrics 2008;12(16) e1440-1477.

5. Anuario Estadístico de Salud 2019. Versión electrónica ISSN: 1561-4433. www.sld.cu/sitios/dne/ o http://bvscuba.sld.cu/anuario-estadistico-de-cuba/

6. Seigel RL, Miller KD, Jemal A. Cancer statistics, 2015, CA Cancer J Clin 2015;65(1):5-29.

7. Siegel RL, Miller KD, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA CANCER J CLIN 2018;0:1–31

8. Armstrong GT, Ross JD. Late cardiotoxicity in again adult survivor of childhood cancer. Prog Pediatr Cardiol 2014;36(1):19-26.

9. Armstrong GT, Kawashima T, Leisenring W, et al. Again and risk of several, disabling, life-threatening and fatal events in the childhood cancer survivor study. J Clin Olin Oncol 2014;32(12);1218-27

10. Auerbach SR, Richmond ME, Lamour JM, et al. BNP levels predict outcome in pediatric hear failure patients: post hoc analysis of the Pediatric Carvedilol Trial. Clin Heart Fail. 2010;3(5):606-11.

11. Hunt SA, Abraham WT WT, Chin MH, et al. 2009 focused update incorporate in2009 focused update incorporate into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adult a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guideline developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiology 2009;53(15):e1-e90.

12. Jones LW, Courneya KS, Mackey JR, Muss HB, Pituskin EN, Scott M,Hornsby, et al . Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum. J Clin Oncol. 2012;30:2530–2537. doi: 10.1200/JCO.2011.39.9014

13. Peel AB, Barlow CE, Leonard D, DeFina LF, Jones LW, Lakoski SG. Cardiorespiratory fitness in survivors of cervical, endometrial, and ovarian cancers: the Cooper Center Longitudinal Study. Gynecol Oncol. 2015;138:394–397. doi: 10.1016/j.ygyno.2015.05.027

14. Peel AB, Thomas SM, Dittus K, Jones LW, Lakoski SG. Cardiorespiratory fitness in breast cancer patients: a call for normative values. J Am Heart Assoc. 2014;3:e000432. doi: 10.1161/JAHA.113.000432

15. Gilchrist SC, Barac A, Ades PA, Alfano CM, Franklin BA, Jones LW, La Gerche A, et al. Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors A Scientific Statement From the American Heart Association Circulation. 2019;139:00–00. DOI: 10.1161/CIR.0000000000000679.

16. Courneya K, Segal R.J, MackeyJ.R, Gelmon K, Reid R, et al. Effects of Aerobic and Resistance Exercise in Breast CancerPatients Receiving Adjuvant Chemotherapy: A MulticenterRandomized Controlled Trial. J Clin Oncol 25:4396-4404.

17. Jones L.J, Eves N.D, Haykowsky M, Freedland S, Mackey J. Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. Lancet Oncol 2009;10:598-605

18. Roger MA, Evan WJ. Changes in skeletal muscle with aging: effects of exercise training. Circulation 2001;104:1358-66

19. Scott JM, Zabor EC, Schwitzer E, Koelwyn GJ, Adams SC, Nilsen TS, Moskowitz CS, et al. Efficacy of exercise therapy on cardiorespiratory fitness in patients with cancer: a systematic review and meta-analysis. J Clin Oncol. 2018;36:2297–2305. doi: 10.1200/JCO.2017.77.5809.

20. Raposeiras Roubın S, Cordero A. La relación bidireccional entre el cáncer y la ateroesclerosis. Rev Esp Cardiol. 2019. https://doi.org/10.1016/j.recesp.2018.12.011

21. Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016;133:1104–1114. doi: 10.1161/CIRCULATION AHA.115.020406

22. Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J lin Oncol. 2005;23:8597–8605. doi: 10.1200/JCO.2005.02.5841

23. Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, Martino S, et al. Cardiac safety analysis of doxorubicin and yclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008;26:1231–1238. doi: 10.1200/JCO.2007.13.5467.

24. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:987–998. doi: 10.1056/NEJMoa1209825.

25. Nichols HB, Trentham-Dietz A, Egan KM, Titus-Ernstoff L, Holmes MD, Bersch AJ, et al. Body mass index before and after breast cancer diagnosis: associations with all-cause, breast cancer, and cardiovascular disease mortality. Cancer Epidemiol Biomarkers Prev. 2009:18:1403–1409. doi: 10.1158/1055-9965.

26. Hanyuda A, Kim SA, Martinez-Fernandez A, et al. Survival benefit of exercise differs by tumor IRS1 expression status in colorectal cancer. Ann Surg Oncol. 2016;23(3):908–917.

27. Holick CN, Newcomb PA, Trentham-Dietz A, et al. Physical activity and survival after diagnosis of invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(2):379–386.

28. Holmes MD, Chen WY, Feskanich D, et al. Physical activity and survival after breast cancer diagnosis. JAMA. 2005;293(20):2479–2486.

29. Inoue-Choi M, Robien K, Lazovich D. Adherence to the WCRF/AICR guidelines for cancer prevention is associated with lower mortality among older female cancer survivors. Cancer Epidemiol Biomarkers Prev. 2013;22(5):792–802.

30. Irwin ML, McTiernan A, Manson JE, et al. Physical activity and survival in postmenopausal women with breast cancer: results from the Women’s Health Initiative. Cancer Prev Res (Phila). 2011;4(4):522–529.

31. Jones LW, Eves ND, Haykowsky M, Joy AA, Douglas PS. Cardiorespiratory exercise testing in clinical oncology research: systematic review and practice recommendations. Lancet Oncol. 2008;9:757–765. doi: 10.1016/S1470-2045(08)70195-5

32. Bamia C. Dietary patterns in association to cancer incidence and survival: concept, current evidence, and suggestions for future research. Eur J Clin Nutr 2018;72(6):818–25.

33. Galiè S, Canudas S, Muralidharan J, García-Gavilán J, Bulló M,Salas-Salvadó J. Impact of Nutrition on Telomere Health: Systematic Review of Observational Cohort Studies and Randomized Clinical Trials. Adv Nutr 2019;00:1–26; doi: https://doi.org/10.1093/advances/nmz107.

34. Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin. 2016 ;66:309-25.

35. Horsley L, Marti K, Jayson GC. Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarker of response to anti-angiogenic therapy. Expert Opin Drug Metab Toxicol 2012;8(3)283-93.

36. Veronese ML, Mosenki A, Flaherty KT, et al. Mechanisms of hypertension associate with BAY 43-9006. J Clin Oncol 2006;24(9):1363-9

37. Robinson ES, Khankin EV, Choueri TK, et al. Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension 2010; 56(6):1131-6.

38. Hall PS, Harshman LC, Srinivas S, Witteles RM. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC Heart Fail. 2013;1:72–78

39. Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A et al. Vascular Toxicities of Cancer Therapies: The Old and the New-An Evolving Avenue. Circulation. 2016;133:1272–1289.

40. Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, Cascinu S. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.Ann Oncol. 2009;20:227-30.

41. Maurea N, Spallarossab P, Cadedduc C, Madonnad R, Melee D, Montef I et al. A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. J Cardiovasc Med 2016 ;17:S93-S104.

42. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.

43. Virani SA, Dent S, Brezden-Masley C, et al. Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy. Can J Cardiol 2016;32:831-41.

44. Gong IY, Verma S, Yan AT, et al. Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study. Breast Cancer Res Treat 2016;157:535-44.

45. Davis MK, Virani SA. Routine prophylactic cardioprotective therapy should not be given to all recipients of potentially cardiotoxic chemotherapy Can J Cardiol 2016;32:926-30.

46. Davis K.M, Virani S.A. Statins in Cardio-oncology: Holy Grail or Epiphenomenon. Can J Cardiol 35 (2019) 142e144.

47. Huelsenbeck J.Henninger C, Schad A, et al. Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity. Cell Death Dis 2011;2e190.

48. Seicean S, Seicean A, Plana JC, et al. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol 2012;60:2384-90.

49. Acar Z, Kale A, Turgut M, et al. Efficiency of atorvastatin in the protection on anthracycline-induce cardiomyopathy. J Am Coll Cardiol 2011;58:988-9.